Recombinant Anti-DLX3 antibody [NCI-R183-14] (ab211492)
Key features and details
- Produced recombinantly (animal-free) for high batch-to-batch consistency and long term security of supply
- Rabbit monoclonal [NCI-R183-14] to DLX3
- Suitable for: WB
- Reacts with: Human
Related conjugates and formulations
Overview
-
Product name
Anti-DLX3 antibody [NCI-R183-14]
See all DLX3 primary antibodies -
Description
Rabbit monoclonal [NCI-R183-14] to DLX3 -
Host species
Rabbit -
Tested applications
Suitable for: WBmore details -
Species reactivity
Reacts with: Human
Predicted to work with: Mouse -
Immunogen
Synthetic peptide. This information is proprietary to Abcam and/or its suppliers.
-
Positive control
- WB: Saos-2 cell transfected with mouse TetOFFv5DLX3/flag TDO untreated with DOX(Doxorubicin 2µg/ml); Saos-2 cell transfected with human TetOFFv5DLX3/flag TDO untreated with DOX(Doxorubicin 2µg/ml).
-
General notes
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free production
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
Properties
-
Form
Liquid -
Storage instructions
Shipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C long term. Avoid freeze / thaw cycle. -
Storage buffer
pH: 7.2
Preservative: 0.01% Sodium azide
Constituents: 59% PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA -
Concentration information loading...
-
Purity
Protein A purified -
Clonality
Monoclonal -
Clone number
NCI-R183-14 -
Isotype
IgG -
Research areas
Associated products
-
Alternative Versions
-
Isotype control
-
Recombinant Protein
Applications
The Abpromise guarantee
Our Abpromise guarantee covers the use of ab211492 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Application | Abreviews | Notes |
---|---|---|
WB |
1/1000. Detects a band of approximately 45, 38 kDa (predicted molecular weight: 32 kDa).
|
Notes |
---|
WB
1/1000. Detects a band of approximately 45, 38 kDa (predicted molecular weight: 32 kDa). |
Target
-
Function
Likely to play a regulatory role in the development of the ventral forebrain. May play a role in craniofacial patterning and morphogenesis. -
Involvement in disease
Defects in DLX3 are a cause of trichodentoosseous syndrome (TDO) [MIM:190320]. TDO is an autosomal dominant syndrome characterized by enamel hypoplasia and hypocalcification with associated strikingly curly hair.
Defects in DLX3 are the cause of amelogenesis imperfecta type 4 (AI4) [MIM:104510]; also known as amelogenesis imperfecta hypomaturation-hypoplastic type with taurodontism. AI4 is an autosomal dominant defect of enamel formation associated with enlarged pulp chambers. -
Sequence similarities
Belongs to the distal-less homeobox family.
Contains 1 homeobox DNA-binding domain. -
Cellular localization
Nucleus. - Information by UniProt
-
Database links
- Entrez Gene: 1747 Human
- Entrez Gene: 13393 Mouse
- Omim: 600525 Human
- SwissProt: O60479 Human
- SwissProt: Q64205 Mouse
- Unigene: 134194 Human
- Unigene: 5194 Mouse
-
Alternative names
- AI4 antibody
- Distal less homeo box 3 antibody
- DLX 3 antibody
see all
Images
-
All lanes : Anti-DLX3 antibody [NCI-R183-14] (ab211492) at 1/1000 dilution
Lane 1 : Saos-2 (Human osteosarcoma cell line) cell transfected with mouse TetOFFv5DLX3/flag TDO treated with DOX(Doxorubicin 2µg/ml)
Lane 2 : Saos-2 (Human osteosarcoma cell line) cell transfected with mouse TetOFFv5DLX3/flag TDO untreated with DOX(Doxorubicin 2µg/ml)
Lane 3 : Saos-2 (Human osteosarcoma cell line) cell transfected with human TetOFFv5DLX3/flag TDO treated with DOX(Doxorubicin 2µg/ml)
Lane 4 : Saos-2 (Human osteosarcoma cell line) cell transfected with human TetOFFv5DLX3/flag TDO untreated with DOX(Doxorubicin 2µg/ml)
Predicted band size: 32 kDa
Observed band size: 38,45 kDa why is the actual band size different from the predicted?
Exposure time: 30 secondsBlocking/Dilution buffer: 5% NFDM/TBST.
This product only recognizes DLX3 carrying the TDO (Tricho-Dento-Osseous syndrome) frameshift mutation.
Datasheets and documents
-
SDS download
-
Datasheet download
Certificate of Compliance
References (0)
ab211492 has not yet been referenced specifically in any publications.